Sonoma Pharmaceuticals, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Leases (Tables)

Leases (Tables)

12 Months Ended

Mar. 31, 2026

Schedule of lease information

Schedule of lease information
		March 31,				March 31,
		2026				2025
Operating leases:
Operating lease right-of-use assets		$	602,000			$	84,000
Operating lease liabilities – current			151,000				58,000
Operating lease liabilities – non-current			469,000				27,000

Other information related to leases is presented below:

		Year ended March 31, 2026				Year ended March 31, 2025
Lease cost
Operating lease cost		$	388,000			$	365,000
Other information:
Operating cash flows from operating leases		$	(515,000	)		$	(174,000	)
Weighted-average remaining lease term – operating leases (in months)			43.5				18.6
Weighted-average discount rate – operating leases			10.7%				6%

Schedule of minimum operating lease liabilities


For Years Ending March 31,
2027		$	210,000
2028			207,000
2029			169,000
2030			161,000
2031			13,000
Total future minimum lease payments, undiscounted			760,000
Less: imputed interest			(140,000	)
Total lease liability		$	620,000